AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 291 min read$ZLAB

Chen Yajing sold $40K of ZLAB

Chen Yajing (Chief Financial Officer) sold 2,264 shares of Zai Lab Ltd (ZLAB) at $17.46 on 2026-06-26.

Original reporting
SEC EDGAR · Chen Yajing
Published Jun 29, 2026, 8:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ZLAB
Neutral
high confidence
Mentioned
$ZLAB
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ZLABNeutralLow
01

Why it matters

The disclosure updates the record of insider activity but does not include any new company performance, guidance, or regulatory/legal event.

02

Market read

Traders may monitor for follow-on insider activity, but this specific transaction is unlikely to drive fundamentals.

03

What to watch

The article provides only one sale; without trend data (multiple filings) or context on liquidity/taxes, the signal may be overstated.

Relevance 3/10Novelty 3/10Timing: after-hours/filing disclosure on 2026-06-29

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Zai Lab Ltd.

Company-level read

Ticker impact

$ZLABNeutralHigh confidence
Context

CFO Chen Yajing filed a Form 4 open-market sale of 2,264 shares at $17.4610 on 2026-06-26, disclosed 2026-06-29.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any impact would be short-lived and sentiment-driven.

Evidence & confidence

The filing is a small-dollar open-market sale with no 10b5-1 plan and no accompanying operational/regulatory catalyst in the text.

Market effects

Sector

No sector read-across; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the CFO sold without a stated 10b5-1 plan, some traders may interpret it as a stronger near-term caution signal than typical planned sales.

Key entities

  • issuer
    Zai Lab Ltd

    Subject of the Form 4 insider transaction; CFO Chen Yajing sold shares.

  • insider
    Chen Yajing

    Chief Financial Officer who reported the open-market sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ZLAB insider trading history →

Related articles

OCT 23
$ZLABMedAI 8/10

Zai Lab’s Zoci Shows 82% Response Rate in Early Lung Cancer Study

Zai Lab's (ZLAB) experimental drug Zoci showed an 82% response rate in an early lung cancer study. The 1.6 mg/kg cohort had 81.9% six-month progression-free survival. Zoci with atezolizumab and carboplatin had a 92.3% response rate but increased toxicity. Zai Lab plans a global Phase III study by 2026, aiming to replace chemotherapy in frontline treatment. The company expects multiple program readouts and a potential U.S. biologics license application submission next year.

finance.yahoo.com2 min
OCT 23
$ZLABHighAI 9/10

Why is Zai Lab stock surging today?

Zai Lab (ZLAB) stock rose 7.2% to $23.62 after releasing Phase 1b trial data for its oncology drug zocilurtatug pelitecan, showing an 81.8% response rate. The company also announced a $250M capital raise from institutional investors. Analysts have an average price target above current levels.

investing.com2 min
OCT 23
$ZLABMedAI 8/10

Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab (ZLAB) reported positive Phase 1b trial results for zocilurtatug pelitecan (zoci) plus atezolizumab in extensive-stage small cell lung cancer (ES-SCLC). The combination achieved an 81.8% response rate and 81.9% 6-month progression-free survival rate. The therapy was well-tolerated, with Grade >3 adverse events in 9.1% of patients. Zai Lab plans to initiate a global Phase 3 trial by year-end 2026.

thailand-business-news.com3 min
OCT 23
$ZLABMedAI 9/10

Zai Lab Limited: Zai Lab's Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer

Zai Lab's (ZLAB) drug zocilurtatug pelitecan (zoci) showed 81.8% response rate and 81.9% 6-month progression-free survival in a Phase 1b trial for extensive-stage small cell lung cancer. The combination with atezolizumab was well-tolerated. A Phase 3 trial is planned for 2026. Zai Lab will discuss the data in an investor call.

finanznachrichten.de3 min
OCT 23
$ZLABHighAI 9/10

Zai Lab reports phase 1b trial data for lung cancer treatment

Zai Lab (ZLAB, 9688) reported Phase 1b trial data for zocilurtatug pelitecan with atezolizumab in lung cancer treatment. At 1.6 mg/kg, 81.8% response rate and 81.9% six-month progression-free survival were observed. Adverse events were mostly mild. A triplet regimen showed 92.3% response rate but higher severe adverse events. Zai Lab plans a Phase 3 study by year-end 2026.

investing.com2 min